Poly-Lactic Acid Magnetoelectric Microspheres for Drug Release Applications by Lakshani Randitha, Gunawardhana Liyanage
i 
 
 
 
 
 
 
 
 
Poly-Lactic Acid Magnetoelectric Microspheres for Drug Release 
Applications 
Gunawardhana Liyanage Lakshani Randitha 
 
This thesis is presented as part of the requirements for the award  
Master of Philosophy [M.Phil] 
from 
The University of Wollongong  
November 2018 
Intelligent Polymer Research Institute [IPRI] 
Australian Institute of Innovative Materials [AIIM] 
The University of Wollongong 
 
ii 
 
ABSTRACT 
The study of magnetoelectric (ME) nanomaterials has drawn significant interest due to their 
novel physical, chemical and mechanical properties. The ME composites, typically made by 
embedding a magnetic substance in a piezoelectric material, exhibit an ME effect described by 
a magnetic-to-electrical signal conversion via an elastic interaction. The ME output voltage 
determines the practicability of the composite for technological applications and biomedical 
applications.  
Polymer-based ME composites are emerging due to their ease of fabrication, flexibility 
and high ME output voltages achieved to date. Furthermore, ME composites are envisaged to 
function as contactless, dispersible electrodes that have potential for remote control of electrical 
stimulation, sensing or release of drugs in biomedical applications. However, only ceramic ME 
composites are recorded in biomedical applications to date. 
Therefore, the aim of the project was to develop, characterize and apply the mechanism 
of magnetic-to-electrical conversion using polymer-based ME nanocomposites, specifically for 
the application of remotely activated drug release. The biodegradable piezoelectric polymer, 
Polylactic Acid (PLA), was used to synthesize polymer microspheres containing magnetic 
CoFe2O4 nanoparticles and characterization of their magnetic and piezoelectric properties was 
undertaken. A key finding was demonstration of controlling the release of drugs (the anti-
inflammatory drug, Dexamethasone) from the ME polymer microspheres via a remotely 
applied magnetic field. While the ME mechanisms affecting the drug release remain unclear, 
several possible theories are discussed.   
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1. Literature Review & Introduction 
 
1.1 Magnetoelectric Materials and the Magnetoelectric Effect 
The early research in ME materials preliminary focused on the single-phase ME materials that 
exhibit both ferroelectric and ferromagnetic properties within the same compound (1, 2). This 
was preliminary found with Cr2O3 (3).  However, further discovery of ME crystals was 
relatively slow until understanding the principles behind coexistence of magnetic and electric 
coupling in Oxides (4). With the theoretical finding of coupling of magnetic and electric, later 
several single-phase ME materials were discovered. For example,  Bismuth-based compounds 
(BiMnO3, BiFeO3), perovskites and Rare Earth (RE) materials such as REMnO3 compounds 
(RE= Y, Ho, Er, Yb) (1). However, these materials are rare and have low permittivity and 
permeability. These compounds are classified into two types, type 1 and type 2, based on the 
origin of their multiferroicity. For type 1 compounds, the ferroelectricity and ferromagnetism 
originate from two different sources which are independent from one another, whereas in type 
2 compounds the magnetism determines the multiferroicity (2). Because of the independent 
origin of multiferroicity in these single-phase materials, they exhibit very small ME 
coefficients, 1-20 mV/cm Oe (5). Besides that, only a few single-phase compounds exhibit an 
ME response at room temperature. For instance, Bismuth ferrite exhibits ME effect at room 
temperature (6). However, single-phase  ME materials are not desirable  for the  short term 
applications because of their low magnetoelectric coefficient values, that are not be able to 
detected (7). Due to the above limitations associated with the single-phase ME materials, the 
ME composites have been developed (5). 
The ferromagnetism of Magnetoelectric (ME) materials are associated with the 
unpaired electrons in d or f shells while a vacant d shell generates ferroelectricity (8, 9). The 
ME effect of these ME materials has drawn significant research attention recently (10). The 
2 
 
application of an external magnetic field to these materials changes the electric polarization of 
the material, and is known as the ME effect. Similarly, the reverse ME effect is where a change 
in magnetization can be generated by an altering an electric field (11).  
ME composites can be fabricated by combining both ferroelectric materials/ 
piezoelectric polymers and ferromagnetic magnetostrictive materials together. BaTiO3, 
PbTiO3, Pb (Zr,Ti)O3, BiFeO3 and Poly vinylidene fluoride (PVDF) are examples for common 
ferroelectric and piezoelectric materials, whereas CoFe2O4 (CFO), NiFe2O4 (NFO), Fe3O4 are 
widely used ferromagnetic materials (10). Though the ME composites demonstrate an ME 
effect, each phase separately does not exhibit the ME effect. The following schematic diagram 
(Figure1.1) illustrates the direct and reverse ME effect (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1-Illustration of a) direct and b) reverse ME effect generation (10). 
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When an external magnetic field is applied to the magnetic phase of the ME material, 
a magneto strictive strain is induced which is then transferred to the piezoelectric phase, 
causing polarization of the material (piezoelectric effect) (Figure 1.1a). This is referred as the 
direct ME effect, which can be described by eq.1 (11). Similarly, an external electric stimulus 
can induced strain on the piezoelectric phase (inverse piezoelectric effect) that is then 
transferred to the magnetic phase, causing a change in the magnetization (Figure 1.1b and eq.2) 
(10, 11). 
 
eq. 1    Direct ME effect =
Magnetic
Mechanical
×
Mechanical
Electric
   
eq. 2    Reverse ME effect =
Electric
Mechanical
×
Mechanical
Magnetic
  
 
ME composites exhibit significantly higher output voltages or ME coefficients compared to 
single-phase ME materials. Importantly, these ME effects can also be seen in higher 
temperatures above room temperature (2). 
The ME effect can be measured using three direct methods: static, quasi-static and 
dynamic method. In the static method, the ME signal is measured with the increasing magnetic 
field. During the measurement, the accumulated charges at the grain boundaries are transferred 
to the electrodes, generating an error in the ME output voltage (12). The second technique, 
quasi-static method, measures the ME signal as a function of time with the changing DC 
magnetic field. However, the technique still cannot resolve the issue of charge accumulation 
(13). Thus, the dynamic method (Figure 1.2) has been developed to overcome the above 
problem by using a lock-in technique. Also, the lock-in technique only measures on a specific 
frequency, that generates low-noise measurements. In this method, both AC and DC magnetic 
fields are applied simultaneously and the ME response is measured as a function of DC 
magnetic field (13).  
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The generated ME output of ME material is expressed using ME coefficient (αME), which is 
denoted as:  
             eq. 3             ∝ 𝑀𝐸 =
V𝑀𝐸
𝑇 × 𝐻𝑎𝑐
 
VME is the actual voltage output monitored by the lock-in amplifier, T is the thickness of 
ferroelectric/PE phase and Hac is the strength of ac magnetic field (14). 
 
 
 
 
 
 
 
 
 
Figure  1.2-Schematic Illustration of  the experimental set up for dynamic ME measurement which 
comprises with  electromagnets for the application of DC magnetic field, Helmholtz coils for  generating 
AC magnetic field, Hallotron/Hall probe is a sensor to measure the actual value of DC magnetic field 
and lock-in amplifier for ME response recording (15). 
 
1.2  Bulk ME Composites 
Although the ME property was first discovered in 1972, the field went dormant until the early 
1990s primarily due to practical limitations in the low ME response. The year 2001 was a major 
step in the development of ME laminate composites containing magnetostrictive (MS) alloy, 
Tb1-x DyxFe2 (Terfenol-D), that later incorporated with piezoelectric materials of PZT, Poly 
vinylidene fluoride and its copolymer Poly(vinylidene fluoride-trifluoroethylene)  (16). Dong 
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et al. (17-19) reported ME composites incorporating Terfenol-D with PZT and Mori et al. (20) 
reported Terfenol-D/Poly vinylidene fluoride ME composites, that generate higher ME outputs 
larger than 1 V/cm Oe.  
 Generally, the ME composites have three common geometric patterns, including 
particulate composites (Figure1.3a), laminates (Figure1.3b) and fibers (Figure1.3c).  These 
structures are denoted as 0-3 (a), 2-2 (b) and 1-3 (c) structures, respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3-Illustration of connectivity patterns in ME composites: (a) particulate composites, (b) 
laminates (c) fibers (d) 0-2 type and (e) 0-0 type nanostructures (f) multiferroic/ferroelectric/magnetic 
nanoring (21). 
More recently, a number of novel geometric pattern nanostructures (22-25) such as 0-
0 and 0-2 type have been demonstrated (21). The 0-0 type nanostructures contain epitaxial 
ferroelectric and ferromagnetic nanodot arrays (Figure 1.3 e) that are reported to increase ME 
coupling over other nanopatterned structures by tolerating the mechanical coupling at atomic 
level (21).  
 0-3 structures are constructed by embedding magnetic particles within a ferroelectric 
matrix and the ME effect of the composites strongly depends on the magnitude of the magnetic 
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field (10).  There are several methods used to synthesize 0-3 particulate composites such as 
sol-gel and spin coating (26). These composites however have a major drawback of current 
leakage that occurs via the movement of dispersed magnetic particles through the matrix that 
allows current to pass through. Recently, sintering techniques were introduced to increase the 
ME coefficient of 0-3 composites, with values in the range of 10-100mV/cm Oe. This is 
because the sintering techniques permit high density packing interactions among particles and 
concurrently reduce the porosity of the matrix (10, 16, 27). 
2-2 laminate structures are developed using alternating ferroelectric and magnetic 
layers. These laminates can be fabricated into different shapes, such as discs, squares, 
rectangles and rings (28). Such laminate structures eliminate the current leakage problem of 
the 0-3 structures (10). Furthermore, the strong interfacial bonding between layers in ME 
laminates enables effective strain transfer to generate large ME responses (26). The 
conductivity of ferrite layers in these laminate structures is not sufficient to act as a conductive 
electrode, which eventually weakens the ME output signal (26, 27). Therefore, an additional 
metal film of Ag or Ni is used to improve the ME signal.   
In contrast to particulate composites, the ME signal of the laminates depend on the 
measurement direction. Thus, the ME coefficient of laminates can be measured in three ways 
with respect to the magnetic field direction; transverse, longitudinal and in-plane longitudinal 
(Figure 1.4) (16). Srinivasan et al. (29-31) using PZT combined with Nickle ferrite (NFO) 
experimentally found that the transverse ME effect was higher than the longitudinal effect. 
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Figure 1.4-Schematic represents of the a) transverse-direction of thickness and b) longitudinal- 
direction of the length, ME measurement directions (32). 
In 1-3 structures, magnetic fibers are incorporated into a ferroelectric matrix, PZT (16). A 
higher ME coupling can be observed in these 1-3 structures due to the 1) effective coupling 
promoted by the large interfacial surface area and 2) reduction of the substrate clamping effect 
(26). However, ME coefficients cannot be directly obtained because of the current leakage 
problem.  
  
 
1.3 Polymeric ME Composites 
Many of the above ceramic-based composites are expensive and fragile and as such they are 
not widely used for practical applications. Therefore, polymer-based ME composites have    
gained significant attention due to their reusable, flexibility and fabrication into a variety of 
forms and shapes (27). Consequently, they can be used for various applications, for example 
CFO/PVDF microspheres are used in biomedical, sensing, actuation, catalysis and energy 
fields (33-35). The polymer shell avoids the particle-particle aggregation by inhibiting 
interactions of the magnetic core, which ultimately increase the dispersion of nanoparticles (36, 
37). 
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The polymer-based ME composites are mainly available in three different types, 
particulates, laminates and polymeric binding structures (11), illustrated in Figure 1.5. 
 
 
 
 
 
Figure 1.5-Illustration of three common polymeric composite types; a) particulates b) laminates and c) 
polymer as a binder composite. 
 
1.3.1 Particulates  
Only a small number of polymeric particulates have described (27), comprising ferromagnetic 
nanoparticles embedded in a piezoelectric polymer matrix. PVDF and polyurethane (PU) 
piezoelectric polymers are commonly used in these types of ME composites (11). PU-based 
ME composites; PU/Fe3O4 and PU/Nickel, can exhibit ME coefficients of >10 mV/cm Oe, with 
the response unexpectedly showing no dependence on the magnetic properties of the magnetic 
constituent (11, 37). Ma et al. (27) reported that the ME coupling is mainly caused by the 
elasticity of the polyurethane. However, still the coupling of these compounds is not well 
understood. 
When considering PVDF based composites, magnetic NFO and CFO nanoparticles 
embedded in P(VDF-TrFE) copolymer matrix demonstrated ME responses of 40 and 41.3 
mV/cm Oe  respectively (5, 38). However, the ME response of PVDF based composites depend 
on the magnetic particles (38, 39). 
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1.3.2 Laminates 
Laminate ME composites were developed to address the leakage current problem in bulk 
nanocomposites. In addition, electrical polling of the piezoelectric phase enhances the ME 
coupling in these composites (11). Different approaches used to fabricate laminate composites 
have been reported.  Cai et al. (40) developed laminates incorporating Terfenol-D/PVDF film 
sandwiched between two PZT-PVDF films. The maximum ME coefficient for the composites 
was reported to be 80 mV/cm Oe. The ME coefficient could reach 3V/cm Oe by increasing the 
frequency of the laminates up to 100 KHz (41). In contrast, Lin et al. (42) constructed laminates 
inserting PZT-PVDF within Terfenol-D/PVDF films and obtained a very high ME coefficient 
of 6V/ cm Oe. The ME signal is dependent on the applied DC voltage in above structures (43).  
The laminates constructed using Metglas and PVDF (Figure 1.6) to date produce the 
highest ME output of 238 and 310 V/cm Oe for unimorph and three-layer structures 
respectively. The higher effective piezomagnetic coefficient (d33) in metglas compared to 
Terfenol-D makes Metglas /PVDF laminates more sensitive towards the applied magnetic field  
(44). 
 
 
 
 
 
Figure 1.6-Metglas and PVDF a) unimorph and b) three-layer laminates 
 
1.3.3 Other Structures  
In these structures (Figure 1.5c), both magnetic and piezoelectric particles are deposited within 
a polymer matrix that acts as a binder. This type of ME composite was first made by dispersing 
Terfenol-D nanoparticles within a PZT and PVDF polymer mixture, The maximum ME 
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coefficient value obtained for these structures was 42 mV/cm Oe (45), with the value depending 
on the amount of Terfenol-D. To enhance the ME coupling, surfactants have been used. Chau 
et al. (46) reported similar structures constructed incorporating, Terfenol-D, PZT with 
Polyethylene, that exhibits ME coefficients of 1.3 mV/cm Oe. 
 
1.4 Factors Affecting ME Effect in Composites  
A good ME response can be obtained when there is strong coupling between the 
magnetostrictive and piezoelectric components. The coupling depends on the connectivity 
pattern and interface bonding of two constituents that facilitates effective strain transfer (47) 
The 0-3 particulate and 1-3 fiber composites are either randomly dispersed or periodically 
aligned (48), exhibiting lower ME responses compared to laminates (2-2 connectivity) that 
have strong mechanical bonding between two phases at the interface. The dispersion of 
magnetic nanoparticles in a larger surface area within a piezoelectric matrix has shown higher 
ME response in 0-3 particulate composites. McDannaled et al. (28) experimentally showed that 
PZT-CFO nanocomposites have a higher ME coefficient at lower CFO concentration. In 
contrast, lower ME coefficients were obtained at higher CFO concentration due to particle 
agglomeration.  
Generally, a higher ME response can be obtained when a constituent of higher 
piezoelectricity (PVDF, P(VDF-TrFE) and PZT) is coupled to a constituent having high 
magnetostriction (Terfenol D and Metglas) (47). When selecting a piezoelectric material, 
factors such as dielectric constant, piezoelectric loss, Curie temperature, piezoelectric strain 
constant, and electromechanical coupling factor should be considered. In addition, the selection 
of magnetostrictive materials considers the magnetic permeability, coercive magnetic field, 
magnetostriction, Curie and Neel temperatures (47). 
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1.5 Piezoelectric Biopolymers and Biodegradable Polymers 
The biopolymers Cellulose and Collagen exhibit inherent piezoelectricity (Table1) due 
to the uniqueness of their molecular structure. The asymmetric crystalline structure of cellulose 
can generate piezoelectricity (49) whereas Deoxyribonucleic acid (DNA) generates its 
piezoelectricity due to rotation of dipoles in the backbone (50). This type of shear 
piezoelectricity is in contrast to that of the commonly used, Poly(vinylidene fluoride) (PVDF), 
where the molecular structure itself does not exhibit inherent piezoelectricity and it is required 
that the dipoles are oriented with an applied stress and/or electrical poling (51). For instance, 
the β-crystalline phase of PVDF exhibits piezoelectricity, in which case the dipoles are aligned 
parallel to the axis of the polymer chain (52). 
  
Table 1: Piezoelectric constants of different bio polymers (53) 
 
 
 
 
 
 
Other than the natural biopolymers, biodegradable polymers like Polylactic acid (PLA), Poly-
3-hydroxybutyrate and Polypropylene oxide exhibit shear piezoelectricity (Figure1.7). These 
biopolymers exhibit small piezoelectric constants that depend on the chirality of the carbon 
atom (53) (Table 2). The biodegradable  Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 
PHBV formed by polymerization of  Poly-3-hydroxy butyrate with 3- hydroxy pentanoic acid 
has been used for drug delivery applications, Pacheco et al. (54) and Lionzo et al. (55). Further, 
Amaro et al. (56) synthesized CFO/PHBV ME composites having various morphologies, 
spheres, fibers and scaffolds, show their potential usage in tissue engineering. Specific to this 
Bio-Polymers Piezoelectric Constant (pC/N) d14 
Cellulose (wood) ⁓ 0.1 
Chitin (crab shell) ⁓ 0.2 
DNA (salmon) 0.07 
Collagen (bone) 0.2 
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thesis, PLA is also a biodegradable piezoelectric polymer previously used to synthesize ME 
composites (57) because of its biocompatible, nontoxic and biodegradable nature (58). PLA 
displays piezoelectricity when in the L-lactic form and is due to polarization changes that occur 
due to the C=O group rotation (59). Several PLA based ME particulate composites have been 
reported. For example,  Correia et al.(60) synthesized CFO/PLA ME composite microspheres 
while Zhang et al. (58) reported Fe3O4/PLA ME composite nanofibers. In general, the use of 
piezoelectric biopolymers in ME composites has been minimal to date though is expected to 
rapidly increase to their several advantages, including inherent piezoelectricity, low-
temperature processing, high flexibility and conformability, high electric breakdown field, 
nontoxicity and biodegradability (39).  
 
 
 
 
 
 
 
 
Figure 1.7-Molecular structures of biodegradable, piezoelectric polymers of Polylactic acid (PLA)- the 
confirmation that generates piezoelectricity, Poly-3-hydroxy butyrate and Polypropylene oxide.  
 
Table 2:  Piezoelectric constants of different biodegradable polymers (53). 
 
 
 
Bio-Polymers Piezoelectric Constant (pC/N) 
Poly-L-lactic acid    d 25 10 
Poly-3-hydroxy butyrate d 25 1.3 
Polypropylene oxide d 25 0.1 
Poly L- lactic acid Poly-3-hydroxybutyric acid Polypropylene Oxide 
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1.6 Core/Shell ME Particulate Composites  
The core/shell ME particulate composites represent a novel advancement in 0-3 connectivity 
to enhance the coupling between two phases and ultimately increase the ME response (8). 
Generally, these particulate composites contain a magnetic core embedded in a piezoelectric 
shell, with either a single or multiple magnetic core (Figure 1.8). Chaudhuri et al. (61) found 
CFO/BTO core/shell ME composites demonstrate a  higher ME coefficient (8130 µV/cm Oe) 
in comparison to standard mixture of CFO and BTO (101 µV/cm Oe). Similarly, Duong et al. 
(62) found these types of core/shell particles exhibit 8 to 18 times higher ME coefficients. In 
addition, reverse core/shell ME composites comprising a magnetic shell and piezoelectric core 
(63), evidently exhibit a converse ME effect (64). 
Mixing of two phases together is the most common approach for fabricating core/shell 
structures, for example, using emulsification, sol-gel methods and electro-spraying (65, 66). 
However, this does not always ensure homogenous dispersion of magnetic particles in the 
piezoelectric matrix, as the magnetic particles tend to agglomerate. If the magnetic particles 
are not well dispersed, their conductivity will result in ME voltage loss due to poor resistance 
and current leakage (67). To improve dispersion and enhance the effective strain transfer from 
the magnetic-to-electric phase, magnetic particles have been treated with a precursor solution 
prior to mixing with the piezoelectric phase (62, 68, 69). For example, Fe3O4 particles were 
treated with oleic acid or citric acid to enhance its stability (70).   
 
 
 
 
 
Figure 1.8-ME particulate composites with different core/shell structures 
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So far distinct types of ceramic (47, 62, 67-69, 71-73), CFO/BTO, Fe3O4/PTO, CFO/PTO, 
CFO/PZT and polymer-based (58, 60, 74-76), CFO/PLA, CFO/PVDF, Fe3O4/PLA ME 
composites have been reported. The majority of research in ME composites has in fact 
investigated the ceramic core/shell composites. Corral-Flores et al. (77) developed CFO/BTO 
ME composites with maximum ME coefficient of 1.48 mV/cm Oe. Also, Curecheriu et al. (78) 
using Ni0.5Zn 0.5Fe2O4/ BTO composites found that these composites have higher dielectric 
properties. 
 
1.6.1 Polymer-based ME Core/Shell Microspheres 
According to the materials used in the synthesis of ME core/shell particles, the latter can be 
classified as inorganic/inorganic (79) and inorganic/organic. Piezoelectric polymer-based ME 
composites are the most common inorganic/organic ME core/shell composites. Generally, the 
polymer shell is formed through electrostatic interactions, osmotic depletion, or hydrogen 
bonding forces onto magnetic core nanoparticles. There are various available techniques for 
the core/shell microsphere synthesis, such as nanoprecipitation (80), ring-opening 
polymerization (76), polymer grafting (81) and sol-gel condensation. Grafting of polymers on 
surface-functionalized magnetic cores demonstrated a higher stability compared to the other 
techniques as it is covalently bonded, for example PLA grafted on Fe3O4, (36). In this thesis, 
we used emulsion techniques for synthesis of core/shell ME polymer composites as it is simple, 
fast and requires less quantity of chemicals (8, 57, 74, 82). Furthermore, there have been only 
a few studies on the ME effect of the polymer-based ME microspheres. Using electrospray 
processing, Goncalves et al. (83) developed CFO/PVDF microspheres that exhibited an ME 
response of 5pC N-1, which avoided some drawbacks of traditional polymer based ME 
composites such as agglomeration and the difficulty in miniaturized form (61).  
15 
 
Of course, there have been numerous studies that have presumably “inadvertently” 
developed ME composite microspheres, i.e. without the specific intention of utilizing the 
classical ME mechanisms described in section 1.1, for a wide-range of application. Ribeiro et 
al.(84) fabricated PVDF ME particles to explore their potential for energy generation and 
storage applications while Maceiras et al. (85) has discussed the use of Polyamide-CFO 
particles as sensors under high temperatures. They have also featured prominently in 
biomedical applications, including for drug delivery systems. Chorny et al. (86) used PLA 
spheres for the Paclitaxel drug delivery. Zhou et al. (87) studied the use of PLGA and PLA-
Fe3O4 ME microspheres for cancer treatment by inserting Interferon into the spheres, whereas 
Zavisova et al. (88) used indomethacin, an anti-inflammatory drug, incorporated into PLA-
Fe3O4  spheres. Similarly, Fengxia et al. (89) studied the same ME system by incorporating 
Curcumin, which is used in cosmetics.  
While there have been extensive studies on the synthesis of core/shell particles, the 
determination of their ME response is relatively unknown and problematic due to several 
reasons. Namely, an ME response can typically only be measured if the particles are compacted 
together to form a bulk film. Henceforth, it is difficult to pinpoint ME measurements on single 
particles. Experimentally, this is a challenging task and the ME voltage responses may be 
expected to also vary from particle to particle due to their non-uniform size distribution. Lastly, 
the alignment of dipoles and piezoelectric geometry consideration in spherical morphology 
structures makes prediction of the piezoelectric response less-well understood.  To address 
some of these challenges, the use of Piezoresponse Force Microscopy to measure the ME effect 
on ME nanostructures such as individual particles and nanofibers has been used (90) .  
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1.7 Biomedical Applications of Core/Shell ME particles 
In recent years, the use of ME particles, specifically via the ME effect, has been demonstrated 
for  drug delivery and regulation of ion channels using magnetic-to-electrical stimulation (91). 
The core/shell ME nanoparticles are generally attractive (92) due to their smaller size, enabling 
interactions with cellular components (82, 93, 94). Secondly, the ability of the particles to 
respond to magnetic stimuli enables them to be magnetically directed or transported to a 
specific site, magnetically controlled for the release of drugs, or magnetoelectric effect for 
stimulation (8, 95). Early research based on pure magnetic nanoparticles with biocompatibility, 
such as Fe3O4 and γ-Fe2O3 (96), used for ME composites to avoid the agglomeration formed 
by pure particles. Having a piezoelectric polymer coating on the magnetic particle surface was 
also beneficial for allowing higher dispersibility (97) and permitting longer circulation without 
recognition by the immune system.  
Studies done by Amaro et al. (56) on synthesized CFO/PHBV ME composites 
demonstrated that these ME systems are also appropriate for biological applications due to their 
non-toxic nature. This is further supported by Rao et al. (67) using CFO/BTO. Besides, Zhao 
et al. (98) reported  that the PLA-based ME composite particles are hemo-compatible.  
 
1.7.1 Drug Delivery and Release 
 
1.7.1.1 Targeted drug delivery using ME carriers 
Targeted drug delivery is a highly promising approach in chemotherapy, particularly for 
selected targeting of tumour cells from normal cells (44, 82, 92, 96, 97). In general, the main 
objective of magnetic carriers is to avoid side effects and reduce the required drug 
concentration for treatment. In targeted drug delivery for chemotherapy, ME nanoparticles 
have been injected into the circulatory system and directed to the tumour site via application 
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of a magnetic field (91). The field strength and size of the particle governs the effectiveness of 
the therapy by targeting the exact affected cells (82, 93, 94). 
  ME particles have been developed for specific drug delivery, especially in 
chemotherapy, but have only been recently reported. Chorny et al. (86) investigated paclitaxel 
loaded PLA ME particles for treatment of a tumour using A10 artery cells. ME nanoparticles 
developed by Nair et al. (99) were applied to anti-HIV drug delivery, where azidothymidine 
50-triphosphate was loaded into CoFe2O4/ BaTiO3 ME nanoparticles.  
 
Figure 1.9-Schematic representation of the process of drug  delivery and release from ME particles 
with an applied magnetic field (91).  
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1.7.1.2 ME Mechanisms for Drug Release 
The mechanism by which the applied magnetic field can induce the drug release may differ 
depending on the design of the ME nanoparticle and applied DC and AC fields. For example, 
in the case where both the ME particle and cell membrane have negative charges, the 
electrostatic repulsion force can facilitate the transport of drug loaded ME nanoparticles 
through a capillary to the tumour site (91, 100). At the site, a field-controlled nano-
electroporation technique firstly can be used to transfer the drug into the cell (Figure 1.9). The 
electric field generated on the drug loaded ME nanoparticles, through an external magnetic 
field via a ME effect changes the polarity of ion channels present on cell membranes of tumour 
cells (8). This enables opening up of pores of the membrane for the penetration of ME 
nanoparticles (100).  
Drug release can also be initiated via the application of an AC magnetic field to break 
bonds on the ME particle surface (67). When the applied DC field (H) is higher than the 
threshold (Hth) for nano-electroporation in tumour cells, an AC external magnetic field then 
facilitates the drug release within the tumour cell. This was implemented using an anti-HIV 
drug, azidothymidine 50-triphosphate (AZTTP) bound to ME nanoparticles via electrostatic 
interactions (Figure 1.10). The induced electric dipole moment within the ME nanoparticles 
upon application of non-zero magnetic field modulated the dipole moment results in the 
breaking of original symmetry of charge and thus breaking the bonds between AZTTP and ME 
nanoparticles to release the drug (Figure 1.10) (101). 
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Figure 1.10-Illustration of drug release from ME particles, a) the charges distribution at ‘0’ field. b) A 
new dipole formation with an applied AC field. c) With the field higher than the threshold, bond 
breakage happens d-e) applied the same field to opposite direction to break the bonds in other sides  
(101). 
 
In order to accomplish drug delivery, ME nanocomposite’s electroporation to enter the 
intercellular environment is crucial. Betal et al. (102) studied the nano-electroporation 
mechanism using CFO/BTO ME composites that enhances internal up take of ME 
nanocomposites via opening of pores on the cell membrane.  
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1.7.2 Cell Identification and Stimulation 
 
1.7.2.1. As a NMR Sensitive Probe 
ME nanoparticles have been applied to identify different types of tumour cells (103) by 
detecting changes in the electric field configuration of cell membranes (103-105). Nagesetti et. 
al (106) found that core/shell CFO/BTO  ME particles  distinguish the electric field of cancer 
cells. This is achieved by the CFO/BTO composites converting the electric signal into a 
magnetic field pattern via the converse ME effect. This magnetic field pattern can then be 
measured by Nuclear Magnetic Resonance Spectroscopy (NMR) system. As illustrated in 
Figure 1.11, three different cancer cells of U87-MG, SKOV-3 and MCF-7 exhibit different 
NMR patterns with ME composites. Thus, these ME composites function as a sensor for 
identifying different cancer cells and their progression stage. Moreover, it was found that the 
NMR output signal for cancer cells are different from normal cells. 
 
 
 
 
 
 
 
 
Figure 1.11-Continuous Wave-NMR spectra for 3 different cancer cell types, glioblastoma cells U87-
MG, ovarian carcinoma cells SKOV-3, breast adenocarcinoma cells MCF-7, in the presence of ME 
nanoparticles (106) . 
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1.7.2.2 Nerve Cell Stimulation 
Guduru et al. (95) studied CFO/BTO ME composite system for brain nerve cell stimulation by 
incorporating ME composite nanoparticles into mice. With an applied magnetic field gradient 
of 3000 Oe/cm, the injected ME composites could enter the brain through the blood brain 
barrier and localize to specific parts of the brain by changing the magnitude of the applied DC 
field. AC magnetic field of 100 Oe in the frequency range of 0-20 Hz is applied to the ME 
composites which then stimulated the brain neural tissue via an electric field generated on 
composites using ME effect. The effect of the stimulation on the brain signals was recorded 
using electroencephalography channels (EEG) (Figure1.12).  
Figure  1.12-Illustration of the brain nerve stimulation process using CFO/BTO composite system; A-
B) Transportation of the ME composites in to specific parts of the brain using DC magnetic field and 
C) brain nerve stimulation using AC magnetic field (95). 
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1.8 Thesis Outlook 
Magnetically directed drug delivery to the target cells and controlled release remotely via the 
ME mechanism has gained recent research attention to develop injectable magnetoelectric 
core/shell composites for biological applications (100, 107). 
To date most of the ME particles have relied upon ME ceramics. CFO/BTO ceramic 
ME composites are mostly studied for drug release applications, Rodzinski et al. (100) and 
Nair et al. (99) and cell stimulation applications, Guduru et al. (95). A few studies have 
demonstrated polymer-based ME particles (86) (58),  however their magnetoelectric 
application in biomedicine is not recorded so far. 
Utilising piezoelectric polymers with biodegradable and biocompatible properties 
would be beneficial for magnetoelectric composites in biomedical applications. For example, 
Poly Lactic acid is extensively used for drug release, Li et al.(89) and Bouza et al. (75). Other 
biocompatible polymers like cellulose (108) and Poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) PHBV (56) have also been used to develop ME composites. Further, the 
studies done by Correia et al. (60) and Amaro et al. (56) demonstrate that these ME composites 
are non-toxic. 
 Therefore, a key focus of the thesis was to explore PLA within ME composites as a 
drug release system. An important consideration was to fabricate microspheres due to their 
advantages in biomedical applications. More specifically, the project aimed to develop and 
apply the mechanism of magnetic-to-electrical conversion using PLA-based ME composite 
microspheres as remotely addressable and contactless polarizable systems, which could be 
applied in drug delivery. The biodegradable and biocompatible nature of PLA would be 
beneficial and the administration of these microspheres relatively practical. This thesis 
describes the synthesis of drug incorporated ME core/shell spheres and investigates their 
application as a controlled drug release system driven via an external magnetic field.  
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Therefore, the aims of thesis are to:  
 
Aim 1: Synthesize magnetoelectric (ME) microspheres based on core/shell magnetic/PLA 
nanoparticles using emulsion methods. The effects of the polymer and magnetic 
nanoparticle concentration on the emulsion synthesis are also investigated. 
 
Aim 2: Characterize the piezoelectric and magnetic properties of the ME microspheres. 
 
Aim 3: Investigate the application of the ME microspheres on drug release of the anti-
inflammatory drug, Dexamethasone, under the control of an externally applied 
magnetic field. 
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2. Materials and Methodology 
 
2.1 Materials 
Materials Company 
Polymers Poly(DL-lactide) 2.0dl/g Corbion Purac, Netherlands 
PolyVinyl Alcohol; Mw: 89000-
98000 
Sigma-Aldrich, Australia 
Nanoparticles Fe3O4 Nanostructured& Amorphous 
Materials Inc., USA 
CFO/ CoFe2O4 Sigma-Aldrich, Australia 
Drug Dexamethasone, micronized, 
USP 
Spectrum Chemical 
 
Solvents Company 
Dichloromethane Fisher Scientific, UK 
Methanol Chem-Supply 
Ethanol Chem-Supply 
PBS pH 7.4 Sigma Aldrich 
Acetonitrile Sigma Aldrich 
 
2.2 Synthesis of PLA-Based ME Composite Microspheres 
Preparation of PLA microspheres comprising magnetic nanoparticles can be achieved via 
different methods, including nanoprecipitation, emulsification, polymerization and sol-gel 
condensation (109). The emulsification method was chosen due to its simplicity, less chemical 
consumption. Both single and double emulsification methods were investigated. In the single 
emulsion method, both the polymer and magnetic particles are in the organic phase, which is 
then emulsified with the PVA surfactant in aqueous medium (58, 60). In the double emulsion 
method, the emulsification is performed twice. Firstly, the polymer in the organic phase is 
emulsified with magnetic particles in aqueous phase to form emulsion 1. Thereafter, the 
mixture is emulsified again with the PVA surfactant in aqueous medium to form emulsion 2 
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(74).  Due to the failure of forming microspheres under conditions described below for the 
double emulsification, all samples in this thesis were prepared from single emulsions. PVA 
was used as the surfactant to increase the stabilization and dispersion of formed microspheres 
(110). 
 
 
2.2.1 Double Emulsion Method  
As explained above in section 2.2, the synthesis via double emulsion method involves having 
polymer and magnetic particles in two different phases, which are immiscible. For the 
following synthesis, water and dichloromethane was selected as the two phases.  
 
2.2.1.1 Synthesis of Fe3O4/PLA Core/Shell Microspheres 
Following previous methods by Gomez-Lopera et. al (74), the procedure was based on the 
water-oil-water (W/O/W) emulsion (See Figure 2.1). 0.6 g of Poly(DL-lactide) was dissolved 
in 40  ml of Dichloromethane. A 20 ml aqueous solution of 20% Fe3O4 magnetic nanoparticles 
was then added to the PLA in Dichloromethane and the mixture was homogenized at 2700 rpm 
for 2 minutes to obtain the first emulsion (W/O). The mixture was added into 250 ml of 1% 
Polyvinyl Alcohol solution, which was homogenized at 2700 rpm for 2 minutes to obtain the 
second (W/O/W) emulsion. The second (W/O/W) emulsion was sonicated at R.T. for 3 hrs to 
evaporate the organic solvent. The resulting microspheres were washed with deionized water 
and centrifuged at 5000 rpm for 10 minutes. Microspheres collected by centrifuge were washed 
again with deionized water several times and freeze dried for 24 hrs until further use. The same 
procedure was repeated to synthesize PLA microspheres without adding magnetic particles. 
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Figure 2.1- Schematic process for the fabrication Fe3O4/PLA core/shell microspheres via double 
emulsion method 
It is noted that the double emulsion method was not used to synthesize CFO/PLA 
spheres, as all the previous work based on CFO/PLA composites are used single emulsion 
method as explained below (60).  
 
2.2.2 Single Emulsion Method  
2.2.2.1 Synthesis of Fe3O4/PLA and CoFe2O4/PLA Core/Shell Microspheres 
Figure 2.2 illustrates the single emulsification process which was used to synthesize 
microspheres. A similar procedure was used based on the oil-in-water (O/W) according to 
previous work in (58). 0.5g of Poly (DL-lactide) was dissolved in10 ml of Dichloromethane 
and 40 mg of Fe3O4 or CoFe2O4 magnetic nanoparticles was added to the PLA in 
Dichloromethane. The mixture was then added to 20 ml of a 1% Polyvinyl Alcohol solution, 
which was homogenized at 1000 rpm for 2 minutes and sonicated at R.T. for 1 hour to 
evaporate DCM. The microsphere suspension was washed with deionized water and collected 
by centrifuging at 5000 rpm for 10 minutes. The microspheres were washed again with 
deionized water several times and freeze dried for 24 hrs. The same procedure was repeated to 
synthesize PLA microspheres without adding magnetic particles. 
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Figure 2.2- Schematic process of the fabrication of CFO/Fe3O4 -PLA core/shell microspheres via single 
emulsion 
To determine the effect of PLA concentration on particle size, microspheres were prepared 
according to the same procedure by maintaining the magnetic nanoparticle concentration 
constant at 0.4 w/v %, with five different PLA concentrations (w/v %) of 1, 2.5,5, 7.5 and 10.  
Similarly, to determine the CFO concentration effect on particle size, microspheres were 
prepared using the above procedure with changing CFO concentrations from 0.2 to 1.2% 
(w/v%) at 5% PLA concentration. Likewise, CFO concentration changes from 0.2-1.2% at 
2.5% PLA concentration. 
 
 
2.2.2.2 Dexamethasone Loaded ME Core/Shell Microspheres 
Due to the success of the single emulsion method using CFO nanoparticles, a modified method 
of Hickey et. al.(111) was used to synthesis core/shell CFO/PLA microspheres loaded with the 
anti-inflammatory drug, Dexamethasone (DEX). 20 mg of Dexamethasone was dissolved in 
10 ml of 9:1 Dichloromethane: Methanol mixture containing 0.5g of Poly(DL-lactide). 40 mg 
of CFO magnetic nanoparticles was then added to the same mixture. Thereafter, the mixture 
was added into 20 ml of a 1% Polyvinyl Alcohol solution, which was homogenized at 1000 
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rpm for 4 minutes and sonicated at R.T. for 5-6 hours to evaporate the organic solvent. Longer 
sonication times were used compared to the above synthesis 2.2.2.2 because the solvent 
mixture of Methanol and Dichloromethane required longer time for evaporation than pure 
Dichloromethane. The microspheres were washed with 1ml of Acetonitrile to remove the traces 
of excess Dexamethasone and centrifuged at 5000 rpm for 10 minutes. The residual 
microspheres were washed with deionized water several times and freeze-dried overnight. The 
same procedure was repeated to synthesize Dexamethasone loaded PLA microspheres without 
adding CFO magnetic particles. 
 
 
2.3 Characterization of Microspheres 
 
2.3.1 SEM/TEM Imaging 
The morphology of the microspheres was imaged using a JEOL-JSM 7500 Scanning Electron 
Microscope (SEM) with accelerating voltage of 5 kV and JEOL-JEM 2010 Transmission 
Electron Microscope (TEM) with accelerating voltage of 200 kV. For SEM imaging, a small 
amount of microspheres were deposited onto carbon tape, which attached to the stub and coated 
with a thin 15 nm Pt layer using sputter coating. For TEM imaging, the samples were prepared 
by dispersing the microspheres in a 50:50 water: ethanol mixture and directly depositing onto 
a TEM grid. The particle size was quantified from SEM images using Image J software. 
Correlation and regression analysis were performed to determine the effect of PLA and CFO 
concentration on particle size.  
 
2.3.2 Dynamic Light Scattering technique (DLS) Analysis 
For the DLS analysis (Zeta Sizer (Malvern Instruments)), 1 mg of CFO/PLA microspheres was 
dissolved in 100 ml of distilled water and sonicated for about 5 minutes before testing. 
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2.3.3 FTIR Analysis   
The FTIR spectroscopic analysis was performed using a Shimadzu FTIR prestige-21 
spectrometer to determine the presence of PLA and either Fe3O4 or CFO in the microspheres. 
The samples were mixed with KBr powder and pressed into a disc to obtain a wide spectral 
range of 500-4500 nm, as otherwise the peaks related to Fe–O bond vibrations cannot be 
detected. Moreover, KBr has no significant absorption lines in this transmittance region and 
does not interfere with the spectrum. The samples of pure solids of PLA, pure CFO and 
CFO/PLA microspheres were directly analysed. 
 
2.3.4 Magnetic Properties   
The magnetic properties of the pure CFO nanoparticles and CFO/PLA microspheres were 
measured using the 14T Physical Property Measurement System (PPMS) in the field range of 
-20,000 to 20,000 Oe at room temperature (data points were obtained at each 500 Oe). The 
obtained data was analysed using the Origin 9.0 software.  
 
2.3.5 Piezoresponse Force Microscopy (PFM)   
Piezoresponse Force Microscopy was used to understand the piezoelectric properties of the 
CFO/PLA microspheres. Samples were prepared by redissolving microspheres in water, 
sonication for a few minutes at room temperature, and then drop cast on a 50mm Pt coated 
glass slide.  A conductive tip (EFM-50, Nanosensors) with Pt/Ir coating and spring constant of 
2.8 N/m was used. PFM height, amplitude and phase images were obtained using Dual AC 
Response Tracking (DART). The contact resonance frequency varied in the range of 285-295 
kHz for different samples. Switching Spectroscopy-PFM (SS-PFM) was used to obtain the 
hysteresis loops. The applied voltage during the SS-PFM measurement was in the range of ± 
29 V, with a frequency of 0.5 Hz. An external amplifier was used to increase the applied voltage 
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to enable a fully saturated switching dynamic. A driving amplitude was set to be 1.2 V for all 
measurements. During the process, 5 cycles of sweeping triangles/square waves were used to 
obtain a single curve which make sure the reproducible results. Igor Pro 6.36 Software was 
used to obtain the hysteresis loops and the data analysis done by using Origin 9.0 Software. 
 
 
 
2.4 Dexamethasone Release from Microspheres with Applied Magnetic 
Fields 
1.5 mg of Dexamethasone loaded microspheres (CFO/PLA and PLA) were dissolved in 15 ml 
of PBS in a centrifuge tube. The tube was placed in a Helmholtz coil and an A.C. magnetic 
field (10 Oe, f=3Hz, Vac=50 mV) was applied continuously for a total of 2 hours. A 0.5 ml 
aliquot of the PBS was removed every 10 minutes, giving a total of 12 samples for 
measurement of the Dex release. The effect of magnetic field strength on drug release was 
investigated by applying 5 Oe, 10 Oe and 20 Oe at a constant frequency of 3 Hz for 1-hour 
duration. Dex loaded PLA microspheres with and without magnetic nanoparticles were also 
tested, in addition to control samples that were measured without applying magnetic field. All 
samples were maintained at pH=7.4 and temp=37° C, by keeping the sample in a water bath 
until the temperature was reached. This is usually done every ten minutes just after the 0.5 ml 
aliquot was taken during the magnetic stimulation. 
However, it is hard to maintain the constant temperature throughout the experiment, it 
varies about 4-5°C degrees because of the fixed distance between the Helmholtz coils in the 
experimental set up was not enough to contain a constant temperature water bath as shown in 
Figure 2.3.  
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Figure 2.3- Experimental set up for the drug release study with the applied magnetic field H a.c. 
 
2.4.1 Dexamethasone Release Analysis using HPLC   
Dex concentration in aliquots was measured using an Agilent HPLC 1260 Quaternary system 
with a ZORBAX ECLIPSE PLUS C18 column. HPLC analysis was carried out at 40ºC with a 
flow rate of 1 ml/min and mobile phase of 35:65 Acetonitrile: water. The acetonitrile/water 
ratio is an important factor; less acetonitrile gives an increase in the elusion time of drug. 
Dexamethasone peak can be seen after 4 minutes of sample injection (10 µl). In the HPLC 
analysis, the dexamethasone was eluted at ~ 4 minutes whereas PBS was eluted at earlier at ~ 
1 minute of which the latter gave a broad peak. This was important as the PBS related peaks 
should not overlap with the compound peak for quantitative analysis. The measurements were 
done at a wavelength of 242 nm, which gives a maximum peak intensity.   
In order to perform apparatus calibration (Fig. 2.4), a standard sample series was 
prepared using a stock solution of 1mg/ml of dexamethasone/ethanol. 0.1 ml of the solution 
was removed and added to an Eppendorf tube with 1.9 ml of PBS and vortexed to mix well. 
Then, 0.8 ml of solution was removed and added to another tube and topped up with 0.8 ml of 
PBS. This was repeated until 10 standards were created (See Table 3). 
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Figure 2. 4-Calibration curve for Dexamethasone standards 
 
Table 3: Standard Dexamethasone sample preparation 
Sample label Concentration (ng/ml) Previous solution (ml) Filtered PBS (ml) 
S1 50000 0.1 1.9 
S2 25000 0.8 0.8 
S3 12500 0.8 0.8 
S4 6250 0.8 0.8 
S5 3125 0.8 0.8 
S6 1562.5 0.8 0.8 
S7 781.3 0.8 0.8 
S8 390.6 0.8 0.8 
S9 195.3 0.8 0.8 
S10 97.7 0.8 0.8 
 
All the samples and standards were filtered into vials using a 0.4 µm syringe filter. The total 
drug release at each time was calculated by adding samples to the previous samples. For 
example, the total cumulative drug released at 30 minutes (T30) = mass of drug released at 30 
minutes (S30) + S20+ S10+ S0 and the average cumulative dexamethasone concentration (ng/ml) 
versus the time (min) was plotted.  Each measurement was repeated 9 times and carried out 
under the same experimental conditions. 
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3. Experimental Results 
 
3.1 Characterization 
 
3.1.1 Morphology of Microspheres 
Commercially available Fe3O4 nanoparticles (Nanostructured& Amorphous Materials Inc., 
USA) with an average size of 30 nm were used in the synthesis (Fig. 3.1a). However, both the 
double and single emulsification synthesis using Fe3O4 nanoparticles failed to form Fe3O4 
nanoparticles/PLA core/shell microspheres (Fig. 3.1b-c). Figure 3.1 b depicts the polymer 
interacting with the Fe3O4 magnetic particles but no spheres were observed. By analysing TEM 
images these observations of the polymer interaction with the magnetic nanoparticles were seen 
rarely in these samples. Failure to synthesize the microspheres is most probably due to the 
lower solubility of Fe3O4 nanoparticles in both aqueous and dichloromethane medium. In order 
to achieve a successful emulsion, the magnetic nanoparticles need to be well dispersed in the 
PLA. The Fe3O4 nanoparticles are commercially supplied with 1% Polyvinylpyrrolidone (PVP) 
as a stabilizer, which clearly makes Fe3O4 nanoparticles insoluble in hydrophobic PLA. This is 
further supported by the successful formation of PLA microspheres in the absence of Fe3O4 
(Fig. 3.1d).  
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Figure 3.1-TEM images of a) pure Fe3O4, b) Fe3O4/PLA obtained by single emulsion, c) Fe3O4/PLA 
obtained double emulsion d) PLA-PVA composite particles 
 
Unlike the Fe3O4 nanoparticles, the commercially available CFO nanoparticles, having 30 nm 
average particle size, were well dispersed in hydrophobic dichloromethane. The single 
emulsion synthesis of CFO nanoparticle/PLA core/shell microspheres was successful in 
producing CFO nanoparticles encapsulated in PLA microspheres (Fig. 3.2). SEM images show 
the microspheres were spherical in shape with smooth surfaces (Fig. 3.2a-b). As shown in 
Figure 3.2a, smaller microspheres were attached to larger CFO/PLA microspheres and Figure 
3.2b shows that some of the pure PLA particles had collapsed. 
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 Figure 3.2-SEM images of a) CFO/PLA microspheres b) pure PLA microspheres 
TEM images in Figure 3.3 illustrate three different microspheres exhibiting an ‘imperfect’ 
perfect core/shell structure, where the CFO nanoparticles (dark areas) were not homogeneously 
dispersed and tended to agglomerate within the PLA microsphere. In particular, uncoated 
magnetic particles could not be observed on the surface, which implies that all magnetic 
particles encapsulated in the polymeric matrix. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3-TEM images of several CFO (dark areas)/PLA microspheres illustrates core/shell structure. 
PLA
A 
CFO 
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For the synthesis, dichloromethane was chosen as the solvent for two reasons, including 
increasing the solubility of PLA and lowering the boiling point (35 ºC) for facilitating 
evaporation of excess DCM at room temperature. This minimized any effect on the 
microsphere synthesis due to further heating, for example, the removal of residual chloroform 
requiring heating (B.P of chloroform is 61 ºC). In addition, qualitative observations showed 
that the homogenization speed was a critical factor, as speeds of > 1200 rpm lead to irregular 
morphologies or break-up of the microspheres, while lower speeds did not support the 
formation of microspheres (60). For this reason, 1000 rpm was selected as an optimum speed 
for the synthesis. 
The diameter of the microspheres was determined by Image J software analysis of SEM 
images (n = 60 spheres). The average diameter of a CFO/PLA microsphere was 3.8 ± 1.6 µm, 
while the DLS technique measured an average size of 2.80 ± 0.07  µm. The difference between 
values from SEM and DLS is believed to be due to latter approach were done in an aqueous 
environment where particles are not homogeneously dispersed, larger particles can be 
aggregated and deposited in the cuvette. Thus, these particle sizes may not be included in the 
final results. The SEM analysis enabled only selected individual microspheres to be considered. 
In contrast, the average size of pure PLA microspheres without magnetic nanoparticles is 8.46 
± 1.5 µm, which is almost twice in size compared to the ME composite microspheres. Upon 
successful synthesis of 0.4% CFO/5% PLA microspheres, further characterization was done 
with spheres prepared under these conditions.  
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3.1.2 FTIR Analysis of ME Microspheres  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4-FTIR spectra of a) CFO/PLA b) pure CFO and c) pure PLA 
 
Figure 3.4 shows FTIR spectra of pure CFO nanoparticles, pure PLA and their CFO/PLA ME 
composites. The peak near 590 cm-1 in spectra of pure CFO and CFO/PLA indicates vibrations 
of the Fe–O bond in CFO. Peaks around the 860-960 cm-1 region in both pure PLA and 
CFO/PLA microspheres represent the polymer backbone stretching, while the bands at 925, 
955 and 1454 cm-1 represents the C–C carbon backbone stretching. The peak at 1751 cm-1 in 
both PLA and CFO/PLA spectra represents stretching vibrations of ester carbonyl, C=O groups 
of the PLA. The weak bands at 1080 and 1451 cm-1 were ascribed to asymmetric vibrations of 
C–H bonds in –CH3. Peaks in the region of 1300-1000 cm-1 represent C–O–C asymmetric 
vibrations. Peaks at 1433 and 1377 cm-1 indicate the asymmetric and symmetric vibrations of 
–CH3 groups. Finally, the absence of 920 and 1510 cm-1 peaks in CFO/PLA spectrum indicates 
that the microspheres are in an amorphous state (60). Thus, we can conclude both the PLA and 
CFO present in the CFO/PLA microspheres.  
 
1300-1000 
a) 
b) 
c) 
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3.1.3 Magnetic Properties of Microspheres 
The magnetic properties of the CFO/PLA ME microspheres were confirmed by applying an 
external magnetic field to the microspheres in aqueous medium. As illustrated in Figure 3.5a, 
the ME composite microspheres were attracted towards the external magnet and completely 
separated out from the solution. Good separation and lack of microspheres remaining in the 
solution also confirmed that CFO nanoparticles were predominately associated with the PLA 
polymer microspheres. Physical Property Measurement System (PPMS) characterization in the 
field range of -20,000 to 20,000 Oe at room temperature (data points were obtained at each 500 
Oe) gave maximum magnetization (MS) values of 56.15 emu/g and 5.17 emu/g for pure 
CoFe2O4 and CoFe2O4/ 5% PLA microspheres, respectively (Fig. 3.5b). It is noted that the 
process used to fabricate the CFO/PLA microspheres has a quite poor efficiency to obtain the 
maximum magnetization value. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5-Magnetic behaviour of the CFO/PLA ME composite microspheres b) Magnetization versus 
applied magnetic field for pure CFO and CFO/PLA 
 
The wt% content of magnetic CFO within the microspheres can be estimated using the 
maximum magnetization values from hysteresis curves in Figure 3.5b and using equation 4.  
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CoFe2O4 wt% in microspheres =
 Maximum  magnetization of microspheres 
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑢𝑟𝑒 CoFe2O4   
× 100         (eq: 4) 
 
Accordingly, only 9% of CFO magnetic nanoparticles were encapsulated in the microspheres, 
presumably due to the CFO nanoparticles not being homogenously dispersed through the 
solution and thus not encapsulated in the PLA during emulsification. Excess CFO nanoparticles 
would then be removed during the washing step. Further PPMS done with 2.5%, 5% and 10% 
PLA microspheres with the same CFO content show that their MS values of 8.57521, 5.17034 
and 4.5684 emu/g decreased with the respective increase in polymer concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6-Magnetization versus applied magnetic field for 2.5% PLA-0.4% CFO, 5% PLA- 0.4% CFO 
and 10% PLA- 0.4% CFO 
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Table 4: Size, magnetization, CFO weight and CFO wt/wt% in PLA microspheres 
 
Table 4 summarizes the effect of the PLA concentration on the CFO encapsulation efficiency, 
confirming a decrease in CFO encapsulation efficiency with increasing PLA concentration. 
One possible reason for this finding is the non-homogenous dispersion of CFO magnetic 
particles during the emulsification process. 
 
 
3.1.4 Piezoelectric Properties of the Spheres 
To understand the piezoelectric effect, it is important to study the dynamics of dielectric 
polarization. Switching Spectroscopy Piezoresponse Force Microscopy (SS-PFM) is a 
technique that provides information on the polarization switching through the nanoscale 
displacement of a piezoelectric material (112, 113). Figure 3.7A illustrates the operating 
principle of Piezoresponse Force Microscopy (PFM). During the PFM measurement, when an 
electric voltage is applied to the conductive tip, Vtip, that is in contact with sample surface, 
eq 5:  Vtip= VDC+VAC Cos ωt 
(VDC is the applied DC voltage, VAC is the driving voltage and ω is the frequency of applied 
bias) the sample displacement occurring due to the piezoelectric effect can be expressed as,  
eq 6:  A=A0+ Aώ Cos (ωt + ϕ) 
PLA 
Concentrati
on (W/V %) 
CFO+PLA 
weight(g) 
CFO 
weight 
(g) 
Spheres maximum 
magnetization 
(emu/g) 
Calculated CFO 
weight in 
microspheres(g) 
Calculated CFO 
wt % in 
microspheres 
2.5 5.896×10-1 4×10-2 8.57521 1.53×10-3 15.27 
5 6.634×10-1 4×10-2 5.17034 9.20 ×10-4 9.21 
10 8.086×10-1 4×10-2 4.56841 8.13×10-4 8.13 
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(A0-equilibrium state, Aώ -Amplitude of the first harmonic of response, ω-the frequency of 
applied bias and ϕ- phase of the electromechanical response) 
The output hysteresis loops of amplitude and phase represent the magnitude of the 
electromechanical coupling (i.e. displacement of the sample) and the polarization direction, 
respectively. For example, the application of an electric field parallel to the polarization 
direction and along that direction causes the sample to expand and contract with the opposite 
polarization (90). 
In SS-PFM, the tip remains in contact with the sample in one X-Y position and the 
hysteresis loops are obtained for both amplitude and phase. The on and off modes of the DC 
voltage enable a more precise measurement of the sample piezoelectricity. During the off mode, 
the response is only based on the piezoelectricity, where electrostatic interactions are not 
involved. In the on mode, it is possible that both the electrostatic interactions and piezoelectric 
effect contribute to the sample displacement (114). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7-A) Piezoelectric property measurement via PFM (113), B) PFM phase hysteresis loop and 
C) PFM amplitude hysteresis loop (115). 
B C 
A 
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As an example, Figure 3.7 B-C illustrates the hysteresis loops of phase and amplitude 
previously obtained for YMO films using SS-PFM. These images show the polarization 
switching behaviour with the applied DC voltage  (115). 
For the PFM measurements in this work, the redispersed microspheres were drop cast 
onto a Pt coated glass slide. Using the optical camera, the tip was placed in location where the 
spheres were homogenously distributed on the substrate, i.e. not visibly aggregates, so as to 
assist in undertaking measurements on individual spheres. A 15× 15 µm2 area of the sample 
was scanned in the PFM mode (Fig. 3.8) to locate a single sphere and then repeated scanning 
was performed in a smaller area (usually 3×3 or 5×5 µm2) to enable accurate positioning of the 
tip on top of individual spheres for the SS-PFM phase and amplitude measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8-PFM height images of CFO/PLA microspheres 
The piezoelectric response can vary from sphere to sphere due to their size distribution. 
For example, Zheng et al. (116) described the piezoelectric response value varies from 240.5 
± 94.7 pm for Fe3O4 /PVDF nanofibers with the size range from 142 ± 29 nm. To overcome 
above issues, we planned to also get an average response from several spheres.  
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9-Piezoelectric property measurement via PFM a) PFM image of CFO/PLA microsphere b-
c), obtained PFM amplitude and phase responses at points 2, 3, 4 and 5 in the sphere. 
Figure 3.9a shows a height image of a single core/shell microsphere. In this case, the 
SS-PFM amplitude and phase responses were measured from four different positions on the 
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sphere and the results for each position given in Figure 3.9 b. As observed in Figure 3.9 b-c, 
there was unexpectedly no amplitude and phase response with the applied voltage. To confirm 
the reproducibility of these results, measurements were carried out on a total of 10 
microspheres. The same observation, i.e. no piezoelectric response, was observed in any of the 
SS-PFM curves (data not shown).   
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3.2 Effect of Emulsification Parameters on Microsphere Size 
3.2.1 Effect of Polymer Concentration 
There are several factors that affect the microsphere size during the emulsification process, 
including the polymer and nanoparticle concentration. Theoretically, increasing the 
mass/concentration of the chemical reactant increases the size of the sphere (117). Figure 3.10A 
qualitatively shows that the size of CFO/PLA microspheres increases with increasing PLA 
concentration. At the highest concentration of 10%, most of the spheres have lost their 
morphology. Statistical analysis of using SEM image analysis and DLS confirmed the 
increasing microsphere size with PLA concentration, with values ranging from ~ 2-10 µm using 
a PLA concentration range from 1-10 W/V % (Fig. 3.10 B). 
  
 
 
 
 
 
 
 
      
 
 
 
 
 
 
Figure 3.10-A) SEM images of CoFe2O4/PLA microspheres in different PLA concentrations1-10% 
(W/V%) and B) A plot of Mean diameter of particles measured by using DLS technique and analysis 
of the SEM image using Image J VS PLA concentration (W/V%), error bars represent standard 
deviation. 
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Statistical T-test show that there was no significant difference between the calculated mean 
diameter values using SEM and DLS (t=0.49; df = 8; p>0.05) (Fig. 3.10).  ANOVA shows that 
there was a significant difference among microsphere size at different PLA concentrations 
(p<0.05), with the exception of between 1-2.5% and 5-7.5% (Fig. 3.11).  
 
Figure 3.11-Statistical ANOVA analysis for SEM measurements, ***/** significant difference p<0.05, 
NS-not significant difference p>0.05. Error bars represent standard deviation. 
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3.2.2 Effect of CFO Concentration  
The effect of the CFO concentration on microsphere size using a constant PLA concentration 
of either 2.5 or 5% was analysed using SEM images (n = 60 microspheres). Figure 3.12 A 
shows that the microspheres maintain their morphology in the CFO concentration range of 0.2-
1.2% when 5% PLA was used. Furthermore, the microspheres appear to be well dispersed at 
1.2% CFO concentration compared to other concentrations (Fig. 3.12A). When the CoFe2O4 
concentration increased to > 1.6%, the microspheres were not formed and lost their morphology 
(Fig. 3.12 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12-A) SEM images of CFO/PLA microspheres in different CFO concentrations 0.2-1.2 % 
W/V at 5% PLA concentration B) the disruption of the morphology of microspheres at 1.6 and 2.0% 
CFO concentration  
A 
B 
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The above study was repeated with 2.5% PLA concentration by similarly varying the CFO 
concentration from 0.2 to 1.2 w/v%. As shown in Figure 3.13A, the microspheres retained their 
spherical morphology throughout the concentration range. Although the spheres were washed 
several times with distilled water, the excess PLA was observed to aggregate and stick onto the 
surface of the spheres (refer to TEM of spheres, Figure 3.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13-A) SEM images of CFO/PLA microspheres in different CFO concentrations of 0.2-1.0 
(W/V%) at 2.5% PLA concentration and B) A plot of Mean diameter of particles measured at different 
CFO concentrations of 0.2-1.2 (W/V %) at 2.5% and 5% PLA concentrations. Error bars represent 
Standard deviation. 
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In contrast to the effect of polymer concentration, the microsphere size significantly decreased 
with an increase in CFO concentration, specifically from 0.2% up to 0.4% (Figure 3.13B). 
Figure 3.13B and further ANOVA analysis (Figure 3.14) shows that apart from a small 
subsequent increase after 0.4 % the increasing CFO concentration did not have an effect of the 
size of the microspheres, i.e. with increasing concentration of 0.6, 0.8 and 1.2%.  
 
Figure 3.14-Statistical ANOVA analysis using 5% PLA, *** significant difference p<0.05, NS-not 
significant difference p>0.05.  
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3.3 CFO/PLA ME Microspheres for Drug Release 
 
3.3.1 Characterization of Dexamethasone-Based microspheres 
During the synthesis of Dex-loaded pure PLA or CFO/PLA microspheres, cleaning was 
performed using Acetonitrile to remove excess traces of dexamethasone, which can adversely 
affect the drug release analysis. SEM images (Figure 3.15) showed that microspheres were 
successfully formed with the addition of dexamethasone into the medium using 5% PLA and 
0.4% CFO concentration. The analysis showed that the Dex-loaded CFO/PLA microsphere 
size was in the range of 5.0±1.3µm (Fig. 3.15A), whereas Dex-loaded PLA microspheres size 
was 6.2±1.7µm (Fig. 3.15B) 
 
 
 
 
 
 
 
 
 
 
Figure 3.15-a) SEM images of drug loaded CFO/PLA microspheres and b) Dex-PLA microspheres. 
 
3.3.2 Drug Release Analysis 
 In the following sections, the percentage of drug release was calculated using equation 7, 
where the initial loaded Dex concentration was 2 mg/ml (111). 
𝒆𝒒 𝟕:     % 𝑇𝑜𝑡𝑎𝑙 𝐷𝑒𝑥 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 =
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝐷𝑒𝑥 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡𝑤𝑜 ℎ𝑜𝑢𝑟𝑠
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑙𝑜𝑎𝑑𝑒𝑑 𝐷𝑒𝑥 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
× 100 
 
Note: For the following sections; 
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• Treated microspheres with magnetic nanoparticles-CFO/PLA microspheres treated 
with magnetic field  
• Treated microspheres without magnetic nanoparticles- PLA microspheres treated with 
magnetic field 
• Untreated microspheres with magnetic nanoparticles-CFO/PLA microspheres not 
treated with magnetic field  
• Untreated microspheres without magnetic nanoparticles- PLA microspheres not 
treated with magnetic field 
 
3.3.2.1 Effect of Magnetic Nanoparticles on Release 
Dex release from both PLA and CFO/PLA microspheres without applying a magnetic field was 
firstly investigated over the 2-hour duration. For both types of microspheres, the Dex release 
exhibited a linear profile, indicative of zero-order drug release kinetics and potentially burst 
release during this time period of the measurement. Fig. 3.16 showed that the incorporation of 
magnetic nanoparticles slightly increased the rate and amount of Dex release. The microspheres 
with magnetic nanoparticles released a total of 2.4% Dex within 2 hours while microspheres 
without magnetic particles released 1.9%Dex. The Dex releasing rates for with and without 
magnetic particles are 1.83 × 10-2 and 1.53 × 10-2 min-1 respectively.  However, statistical data 
analysis showed no significant difference between the mean amount of drug release for PLA 
and CFO/PLA microspheres without the application of magnetic field (p=0.25). 
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Figure 3.16-Dexamethasone released from PLA and CFO/PLA microspheres without applying 
magnetic field, within the vitro release studies in PBS (pH =7.4, temp=37 °C, n=9) 
 
Since both type of microspheres has an equal amount of Dex loaded, it would be 
expected that the CFO/PLA has a higher drug release rate due to the smaller particle diameter 
compared to only pure PLA microspheres. This is because smaller polymer microspheres have 
higher surface/volume ratio, which enhances the release rate under the same experimental 
conditions (58). Nevertheless, no significant difference was observed between the means of the 
microspheres with versus without CFO nanoparticles, suggesting that effects other than particle 
size, such as the presence of CFO that may act as a barrier to Dex release, may also contribute 
to (in this case offset) the rate of drug release. 
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3.3.2.2 Effect of Magnetic Field on Drug Release (Without Magnetic Nanoparticles) 
The effect of an applied magnetic field on Dex release was initially investigated by exposing 
the microspheres to a constant 10 Oe a.c. magnetic field (f=3Hz, Vac=50 mV) over 2 hours. 
Fig.3.17 showed that microspheres treated with and without a magnetic field gave a linear 
response, again indicative of zero-order drug or burst release kinetics. The PLA microspheres 
released a total of 1.5% and 1.9% Dex with and without an applied magnetic field, respectively, 
within 2 hours and the Dex releasing rates for treated and untreated samples were 1.18 × 10-2 
and 1.53 × 10-2 min-1. No significant difference (p=0.62) was observed between means during 
the release period, confirming that the magnetic field had no effect on the drug release from 
only PLA microspheres. 
 
 
Figure 3.17-Cumulative Dexamethasone released from PLA microspheres with and without treated 
with magnetic field, within the vitro release studies in PBS (pH =7.4, temp=37 °C, n=9) 
y = 0.2357x + 1.6196
y = 0.3055x - 0.4496
0
10
20
30
40
50
60
0 20 40 60 80 100 120 140
C
u
m
u
la
ti
ve
 r
el
ea
se
d
 D
ex
 c
o
n
ce
n
tr
at
io
n
 (
u
g/
m
l)
Time (Min)
Treated without
magnetic particles
Untreated without
magnetic particles
54 
 
3.3.2.3 Combined Magnetoelectric Effect of CFO Nanoparticles and Magnetic Field  
To demonstrate a synergistic, or ‘magnetoelectric’, effect of combining magnetic nanoparticles 
with magnetic stimulation, Figure 3.18 shows a comparison of Dex release from all the 
different treated samples. 
 
 
Figure 3.18-Cumulative dexamethasone released from microspheres within the vitro release studies in 
PBS (pH 7.4, temp= 37 °C, n=9), MNP-effect of magnetic nanoparticles, MF -effect of magnetic field 
and MNP+MF -Combine synergistic effect 
 
Figure 3.18 again shows the individual effect of either magnetic nanoparticle 
incorporation (MNP (blue)) or magnetic field (MF (yellow)), respectively, versus the control (grey). 
Dex release for combining both the magnetic nanoparticles and magnetic field (MNP+MF (red)) 
is also plotted to compare a synergistic effect from the magnetically stimulated CFO/PLA 
microspheres. Significantly, statistical ANOVA showed a significant difference of Dex release 
between the untreated CFO/PLA (MNP (blue)) and magnetically stimulated CFO/PLA sample 
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(MNP+MF (red)). The microspheres released 1.0% and 2.4% of Dex from magnetically stimulated 
CFO/PLA and untreated CFO/PLA samples, respectively, indicating that the combination of 
both magnetic nanoparticles and magnetic field caused a significant decrease in Dex release. 
In addition, the releasing rates for treated and untreated CFO/PLA samples were 0.86× 10-2 
and 1.83 × 10-2 min-1 respectively. 
 
Figure 3.19 summarises all the data obtained for the different experimental conditions. 
By considering all the observations, we can conclude 1) that magnetic stimulation of PLA 
microspheres without CFO nanoparticles (yellow) does not have a significant effect on the rate 
of Dex release (versus grey control). Though it is observed that their release rates show an 
increasing deviation over time, particularly beyond 60 min, i.e. the release from treated PLA 
microspheres decrease (yellow) while the untreated microspheres increase (grey). 2) The 
addition of CFO MNP (blue) increased the rate of Dex release even without applying magnetic 
field. However, it is noted that statistical significance was not observed between the values 
(versus grey control). 3) Finally, a significant finding was that by applying a magnetic field to 
PLA microspheres with CFO MNP the rate of Dex release significantly decreased from the onset 
of the experiments. 
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Figure 3.19-Cumulative dexamethasone released from CFO/PLA and PLA microspheres with and 
without application of magnetic field, within the vitro release studies in PBS (pH 7.4, temp= 37 °C, 
n=9). 
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4. Discussion 
 
4.1 Synthesis of Microspheres and Factors Influence on Size 
Synthesis of ME core/shell spheres via emulsion techniques is a promising approach for 
obtaining microspheres and nanoparticles. Before encapsulation of the magnetic nanoparticles, 
they should be well-dispersed in the polymer solution. Accordingly, hydrophilic Fe3O4 and 
CFO magnetic nanoparticles can be dispersed in hydrophilic polymers though less so in the 
case of hydrophobic polymers. To increase hydrophobicity of these magnetic nanoparticles, 
surface treatment with oleic acid and sodium dodecylsulphate (SDS) has been used (109). Yet 
it is interesting to find that most of the literature reports successful synthesis of magnetoelectric 
(ME) composite with only untreated magnetic nanoparticles (60, 74).  
Gomez-Lopera et al. (74) and Okassa et al. (118) previously synthesized PLA ME 
composite sub-micron spheres within the size range of  130-230 nm and 268-327 nm, 
respectively, using double emulsion synthesis with Fe3O4 magnetic particles. However, in this 
work, we were unable to synthesize ME core/shell microspheres using the double emulsion 
method, as explained in section 2.2.1.1. In the previous studies (74, 118), the synthesis was 
done using their own synthesized Fe3O4 magnetic particles, while we used commercially 
obtained nanoparticles comprising 1% Polyvinylpyrrolidone (PVP). Thus, they were unable to 
be encapsulated in the PLA and form microspheres as described earlier in section 3.1.1. 
Asmatulu et al. (119) used the single emulsion synthesis approach with PLA and Fe3O4, 
producing ME spheres in the range of 268-327 nm and Zhang et al. (58)  produced spheres 
with 0.8-2.4 µm size using the same approach. Similarly, the spheres synthesized by Correia 
et al. (60) using CoFe2O4 magnetic nanoparticles obtained PLA ME spheres of 0.8-2.2 µm size, 
which is smaller than those obtained in this work (3.4-4.2 µm). This microsphere size 
difference can be caused by the emulsification speed which they do not specify in the literature. 
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However, the major drawback of the emulsification method is the broad size distribution of 
particles(120).  
The particle size is a crucial factor for drug release using polymer-based microspheres. 
Because of the higher surface area-to-volume ratio, smaller sized spheres show higher rate of 
drug release, which decreases with increasing particle size. It is easier for the drug to interact 
with solvent, as the solvent only needs to penetrate less of a distance for smaller particles (121). 
In contrast, Berkland et al. (122) found that larger particles had a higher rate of polymer 
degradation, eventually leading to accelerated rate of drug release. In addition, it has been 
shown that particle size directly affects the drug distribution within the spheres. During 
synthesis, some drugs may lose their exterior hydrophilic nature due to limited solubility of the 
polymer matrix. This tends to increase the local drug concentration near the outer surface, thus 
leading to non-uniform drug distribution within the sphere. Smaller particles show a more 
uniform drug distribution because the drug needs to travel less distance compared to larger 
microspheres. Finally, the particle size also affects the drug delivery rates via their interaction 
in the body. For instance, in pulmonary-based drug delivery, larger particles can accumulate in 
the respiratory tract before entering into the lungs, while smaller particles aggregate together 
before entering to the target or otherwise detected and removed by phagocytosis (120). In this 
thesis, we sought to investigate the effect of polymer and magnetic nanoparticle concentration 
on microsphere size. 
 
 
4.1.1 PLA Concentration 
According to the Figure, 3.10, the microsphere size shows a positive relationship with 
increasing PLA concentration. The observation may be attributed to the increase in PLA that 
results in increasing viscosity of the dispersed phase, causing the emulsified droplets to 
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undergo coalescence during synthesis and leading to an increase in microsphere size (123).  
Likewise, Freitas et al. (124) and Dinarvand et al. (117) changed the PLA concentration in the 
range of 0.05-0.15% and 2.5-4%, respectively, finding that the particle diameter increased with 
higher polymer concentrations. This is further supported by studies done by Jeffery et al. (125)  
and Rodrigues et al. (126) where they used Poly-lactide-co-glycolide (PLGA) and Dextran as 
the polymer, respectively. Furthermore, Freitas et al. (124) found that the combination of three 
parameters;  PLA concentration, stirring rate and volume of the aqueous phase controlled the 
particle size. 
 
4.1.2 CFO Concentration 
The results described in Figure 3.13B shows that the micro size is largest at 0.2% CFO. Beyond 
this concentration, > 0.2%, there is a significant decrease in microsphere size but no further 
dependence on increasing concentration is observed.  Goncalves et al. (83) similarly found that 
the microsphere diameter was independent of the inner CFO content.  Even when the CFO 
inner content was varied from 5-27%, the sphere diameter remained within the range of 3-7 
µm. We effectively observed a similar result though because the CFO concentration range of 
0.4-1.2% was much lower and we were able to observe a critical concentration 0.2%, where 
there was an effect.  
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4.2 Properties of Microspheres 
 
4.2.1 Magnetic Properties 
Similar studies done by Correia et al. (60) found that 40% of CFO nanoparticles were 
encapsulated within the CFO/PLA microspheres, which is very high compared to our 
maximum of 15%. The possible reason behind this variation can be the solubility of the 
polymer. In this case, the previous study used PLA with molecular weights ⁓200,000 g/mol-1 
whereas we used a higher molecular weight of ~ 300,000 g/mol-1, which may not disperse the 
CFO nanoparticles as easily and therefore the encapsulation efficiency is higher.  Studies done 
by Goncalves et al. (83) using CFO/PVDF microspheres fabricated via electro spraying 
demonstrated ⁓30% encapsulation efficiency. Theoretically, in chemical synthesis, CFO 
nanoparticles can be sedimented in the solution whereas electro spraying is more likely to 
produce a homogenous (aerosol) distribution, leading to increased encapsulation efficiency.  
 
4.2.2 Piezoelectric Properties 
Piezoelectric materials can generate an electric charge in response to an applied mechanical 
stress. The (PLLA) Poly (L-lactic acid) chiral form of PLA exhibits shear piezoelectricity (127) 
yet we were unable to detect any piezoelectric response in the amplitude or phase signals of 
the PFM measurements. This may be due to several reasons, including that the PLA is a 
polymer that exhibits shear piezoelectricity, approximately 10 pC/N (128). This 
piezoelectricity is naturally inherent within their chiral structure and due to rotation of 
permanent dipoles in the uniaxial oriented molecule (Fig. 4.1A). To enable a piezoresponse, 
dipoles of the PLA therefore need be arranged uniaxially, as illustrated in Figure 4.1A (129). 
This gives rise to electric displacement of PLA response to a mechanical stress in the directions 
of d14 and d25 (Fig.4.1C). Thus, shear piezoelectricity is exhibited. In this work, it is hard to 
61 
 
distinguish the direction of dipoles in a microsphere. It is expected that a response would only 
be detected if measured in the corresponding direction, i.e. lateral direction for shear 
displacement. Related to this, the shear piezoresponse of the microspheres may very small and 
difficult to detect, A shear displacement may possibly show up in the normal direction in SS-
PFM yet this was evidently not the case.  
  
 
 
 
 
 
 
 
 
 
 
Figure 4.1-A) Schematic diagram of PLA showing its permanent dipole direction (129) B) Illustration 
of the direction of positive and negative polarity and the stress direction of d33 and C) piezoelectric 
directions of drawn chiral PLLA polymer (130).  
 
A lack of piezoresponse may also be exacerbated by the amorphous nature of the PLA, as 
indicated by the absence of bands 920 and 1510 cm-1 in FTIR spectrum in Figure 3.4. For 
example,  most of the piezoelectric polymers, for example PVDF and PLA, show increased 
piezoelectricity with a higher crystalline content (59). In addition, previous studies (83, 116) 
using electrospinning or electrospraying for making PLA films and fibers enhance the polarity 
(A) (B
(C
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by stretching the polymer and also applying a high voltage electric field to increase the 
piezoresponse. Due to the inherent piezoelectric properties of the PLA, an electrical field or 
poling should not be essential to generate piezoresponse as in the case of PVDF (130). Though 
Sencadas et al. (131) demonstrated piezoelectricity of PLA nanofibers by electric poling using 
PFM and showed that increasing the poling voltage results in greater piezoelectric response 
(Fig.4.2). In contrast to electrospinning and spraying, the emulsion technique is not likely to 
induce strain on the polymer. Alternatively, the polymer cannot be stretched or ’drawn’ after 
fabrication with emulsion synthesis and spheres (132, 133).   
    
Figure 4.2-PLLA nanofibers poled at a)100 V, b)200 V and c) the measured piezoelectric response of 
X at 100 V (blue) and 200 V (red) (131). 
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4.3 Polymeric Microspheres for Drug Release  
Polymer-based microspheres are perfect carriers for drug delivery applications due to their 
biocompatibility, ease at incorporating various drugs, controlled drug delivery and release, 
minimal side-effects and reduce dosage (111). These polymeric microspheres can incorporate 
various biological materials used for protein therapeutics. For example, Castellanos et al. (134) 
and Li et al. (135) studied PEG-PLGA microsphere systems encapsulating y-chymotrypsin and 
glucose oxidase proteins. Hedley et al. (136) and Capan et al. (137) studied plasmid DNA 
encapsulated PLGA microspheres for gene therapy.  
Major mechanisms involved in the drug release (138) are degradation of the polymer 
shell, diffusion of drug through the polymer matrix, and release via both polymer degradation 
and drug diffusion (Fig. 4.3). The release rates are determined by the microsphere size, 
structure; polymeric properties of molecular weight, crystallinity and copolymer ratio; and 
interactions between the polymer and drug (and physical properties of the drug) (139). In 
addition, factors like medium, pH and temperature of the medium also affects the drug release 
rate (140). 
 
 
 
 
 
 
Figure 4.3-Illustration of different drug release mechanisms from polymer-based spheres (138). 
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4.3.1 Types of Drug Release Profiles 
Figure 4.4 illustrates three basic drug release profiles. The type 1 represents the burst release, 
the type 2 corresponds to the two-phase release, including initial burst and saturation, and the 
type 3 represents three-phase release profile having initial burst, saturation and secondary burst 
stages. The burst release stage can be caused by the formation of large pores in the polymer 
matrix, free drug particles accumulated within microspheres, diffusion of drug particles located 
on the surface or breakdown of microspheres. If the drug is hydrophilic, it can quickly diffuse 
through aqueous medium and the time consuming for burst release is less compared to 
hydrophobic drugs.  In the saturation stage, there is slower drug release which occurs through 
few pores in the highly dense polymer matrix. Finally, a secondary burst stage can occur due 
to degradation and the collapse of microspheres (140). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4-Drug release profiles for PLA, PLGA microspheres (140). 
 
4.3.2 Smart Release Systems 
Smart release systems of hydrogels, polymeric disks, rods, pellets and microspheres are 
developed to overcome the difficulties of controlled drug release associated with traditional 
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drug delivery systems. To cure some diseases, it is required to maintain a constant drug 
concentration, thus curtailing the burst release is required. Alternatively, the release of drugs 
like antibiotics and pain killers may benefit from burst release at various time intervals, 
emphasizing the importance of tailoring the release profile (120). 
Core/shell microspheres are such structures used to control the rate of drug release, 
particularly the development of an outer shell which is important. For example, studies done 
by Huang et al. (141) using lidocaine drug found that gelatine coated on PLA/PEG 
microspheres showed a significant decrease in burst release and  the time duration for total 
release increased.  Polyethylene glycol (PEG) has higher hydration characteristics which 
allows the hydrophilic lidocaine to easily dissolve and release through diffusional transport, 
giving initial higher burst release of ~ 60%. The surface coating of gelatine reduces the initial 
burst by 98% by formation of strong hydrogen bonding with PEG. Similarly, Chan et al. (142) 
studied Docetaxel release from PLGA-Lecithin-PEG core/shell microsphere system and found 
that changing the lipid or Lecithin/ polymer ratio from 0.1 to 100% reduced the Docetaxel 
release rate from 50% within 20 h (Fig. 4.5). Further, they discussed that the individual 
changing of PLGA or PEG surface density does not affect the releasing rate. It was suggested 
that the lipid layer acts as a barrier to control drug release by keeping Docetaxel molecules in 
the hydrophobic core and avoid penetration of H2O molecules in to the core. 
 
 
 
 
Figure 4.5 -A) illustration of PLGA-Lecithin-PEG core/shell structure and B) Docetaxel releasing rates 
with changing Lecithin/polymer ratio (142). 
A B 
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In addition, studies have  developed targeted drug release through a pH sensitive shell, 
where the release can be tuned with pH (143). Soppimath et al. (144) studied the Doxorubicin 
anticancer drug releasing rates for a folate conjugated poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide-co-10-undecenoic acid) P(NIPAAm-co-DMMAm-co-UA)/cholesterol 
core/shell nanoparticle system at different pH of 7.4, 6.6 and 5.0.  The release rates were lower 
at pH 7.4, which was 25% after 48h while the particles in medium of pH 5.0 and 6.6 released 
64% and 54% after 48h, respectively, because of the deformation of the core/shell structure in 
the acidic medium. In addition, the initial burst also decreased with the increasing pH. 
 
4.3.4 Magnetically Controlled Drug Release 
The drug release can be stimulated using an external magnetic field. To date most of the 
research in this area is based on magnetic hydrogels (7, 145). Satarkar et al. (146) reported 
magnetic hydrogel nanocomposites synthesized with Fe3O4 nanoparticles in temperature 
sensitive poly(N-isopropylacrylamide) hydrogels for remotely controlled release of Vitamin 
B12. They continuously applied 297 kHz high frequency with 5.3 kA/m alternating magnetic 
field to hydrogel discs and found an increase in Vitamin B12 release compared to the control 
without an applied magnetic field. The magnetic field caused a temperature increase within the 
nanocomposite that leads to collapse of the particles and increased release of drug. Further 
studies with Methylene blue instead of Vitamin B12 with the magnetic field of 10 min ON and 
20 min OFF gave higher release rates in the ON mode. Similarly, Meenach et al. (147) 
developed PEG based magnetic hydrogels incorporating anti-cancer drugs Methyl ether 
methacrylate and Tetra(ethylene glycol) dimethacrylate (TEGDMA). These hydrogel discs 
were magnetically stimulated using 297 kHz high frequency alternating magnetic field of 25 
kA/m. 
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4.3.5 Magnetoelectrically Controlled Drug Release 
To date polymer-based systems using magnetoelectric effects for drug release have not been 
recorded, rather ceramic ME composites such as CFO/BTO have been studied (67, 99), as 
described in section 1.7.1. 
The drug release via ME composites occurs through the breakage of bonds with the application 
of an AC magnetic field, as explained in section 1.6.1. The applied external magnetic field 
induces stress within the magnetic particles which is then transferred to the ferroelectric 
constitute. Then displacement of charges in the ME composite change the dipole moment and 
cause the bond breakage.  
 
4.3.6 Dexamethasone Release Study Using CFO/PLA ME Microspheres 
The following section 4.3.6 discusses the ME controlled drug release using CFO/PLA polymer-
based microspheres which have not yet to be described in the literature. 
 
4.3.6.1 Effect of Magnetic Nanoparticles  
The incorporation of the CFO magnetic nanoparticles reduces the microsphere size as 
described in section 3.3.3.1 (Fig 3.15). Thus, a higher drug release rate from CFO/PLA 
microspheres compared to PLA microspheres was reasonably expected.  However, the 
presence of CFO nanoparticles in the polymer may also hinder, e.g. block, the diffusion 
pathway of the Dex, resulting in an opposing decrease in release rate. Accordingly, there was 
no significant difference between the release rates of CFO/PLA and PLA microspheres, as 
shown in Figure 3.16, possibly suggesting the interplay of the aforementioned effect of 
microsphere size versus CFO nanoparticles on diffusion.   
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4.3.6.2 Effect of Magnetic Field  
Figure 3.17 (section 3.3.2.2) showed that the application of a magnetic field by itself 
(to pure PLA microspheres) had no significant effect on the drug release. Theoretically, when 
a changing magnetic field is applied to a conducting solution, e.g. electrolyte or biological 
medium, an electromotive force can be generated on the system, known as induction (148). 
Related to drug release, this induction mechanism was nicely demonstrated by Gao et al. (149) 
who applied a magnetic field to Dex loaded conducting polymer, polypyrrole nanofilms and 
nanowires. They found that the Dex release rate significantly increased with the applied 
magnetic field, explained by an induction effect that causes electrochemical redox changes in 
the polypyrrole and its overall net charge that breaks the electrostatic interactions with Dex to 
increase the release rate. While an induction can effect in our solution with the movement of 
ions, it does not influence the Dex interaction with polymer or its diffusion.  
 
4.3.6.3 Synergetic Effect of Magnetic Nanoparticles and Magnetic Field 
While the incorporation of either magnetic nanoparticles or applied magnetic field does not 
have a significant effect on the Dex release, a main finding in the thesis is that a synergistic 
effect exists between the two, as given in Figure 3.18 (section 3.3.2.3). In particular, it was 
observed that the application of the magnetic field to CFO/PLA microspheres reduced the total 
percentage release by 1.4 %. At this stage, the release mechanism is not well understood. By 
way of deduction, the role of induction, as described above, does not appear to play a significant 
role given the lack of an effect in Figure 3.17. We therefore suggest that other possible 
mechanisms, which are described below. 
 
69 
 
4.3.6.4 Possible Mechanisms for Dexamethasone Releasing Rate of CFO/PLA 
Microspheres 
Firstly, the microsphere system initially electro-statistically equilibrates with charges of 
CFO/PLA and Dex. Once the magnetic field is applied to the system, the polarity change of 
the piezoelectric polymer (using the conventional theory of ME effect (Section 1.7.1)) could 
break the electrostatic interactions, or hydrogen bonding between the partially charged Oδ-–Hδ+ 
groups of polymer and lone pairs in O atoms of the drug or vice versa. Thus, this could increase 
the release of drug from the microspheres. On the other hand, if the polarization is in the 
opposite direction, then it is possible that the electrostatic interactions may be stronger and the 
rate of drug release is reduced due to charge leakage to the CFO, which could affect the Dex 
interaction and lead to the results obtained in section 3.3.2.3 (Fig. 3.18). However, we were not 
able to observe a piezoelectric response of the PLA, as described in section 3.1.4, and as such 
further investigation is required to confirm the above mechanism. Furthermore, it is also 
important to measure “true” ME effect whereby a change in the piezoelectric response (e.g. 
PFM amplitude) is detected while applying a magnetic field (116). 
 
According to the above mechanism, or conventional ME effect, the magnetic particles 
undergo expansion and contraction (magnetostriction), which induces strain on the 
piezoelectric PLA. In contrast, a second mechanism is based on the physical movement of 
magnetic nanoparticles due to the applied magnetic field.  
 
In this case, when there is a magnetic field applied to the system, the magnetic particles 
physically move over some XYZ distance. This displacement of the magnetic particles then 
leads to occupation of pores. Thus, the drug diffusion pathways are blocked and reduce the 
releasing rates.  
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5. General Conclusion 
In conclusion, the project was focused on the development and characterisation of injectable 
CFO/PLA microsphere systems for controlled drug delivery and release applications. I 
successfully synthesized the CFO/PLA ME microspheres via W/O emulsion synthesis, with an 
average particle size of 3.8±1.6 µm at 5% PLA and 0.4% CFO. Further, I demonstrated the size 
of microspheres increased with increasing PLA concentration from 1% to 10%, while there is 
no trend with CFO concentration increase from 0.4% to1.2%.  
 
The CFO/PLA microspheres demonstrated their magnetic character, with separation in 
solution and retentions of 8-15% CFO. However, we were not able to confirm their 
piezoelectricity, thus the aim of synthesising magnetoelectric spheres was not established.  
 
Nevertheless, the microspheres could be produced in the presence of Dexamethasone 
and significantly the application of 10 Oe external alternating magnetic field to CFO/PLA 
microspheres revealed a synergetic effect by causing a decrease in the Dexamethasone release. 
While the investigation of the mechanism of the release was not the scope of this thesis and is 
not fully understood, the ability to reduce the releasing Dexamethasone rate opens up the 
possibility of modulating the release profile.  
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6. Future Work 
Initially, it is important to understand the mechanisms behind the drug release with the 
application of a magnetic field for these ME particulates. I have discussed possible mechanisms 
for drug release in the section 4.3.6.4 though they are still not well understood. However, the 
mechanisms of drug release with ceramic composites like CFO/BTO is explained Nair et al. 
(99), where the AZTTP drug molecules are released by the breakage of bonds with applied 
magnetic field. Thus, modifying the structure of polymer and drug would possibly enable a 
well-defined approach for magnetoelectric composites. 
Trying different fabrication methods could be important. The fabrication using novel 
technologies like coaxial 3-D printing or electrospraying would be a worthwhile approach. 3-
D printed polymeric composites offers many advantageous, including high precision, cost 
effective and ability to generate customized shapes (Fig. 6.1) (150).  Similarly, electro-spraying 
allows the formation of ME microspheres with higher magnetic content encapsulated and 
resulting reproducible unique size of spheres (83).  
 
Figure 6.1- A) 3-D printed PLA scaffolds incorporating with Poly-Dopamine and Xu-Duan, a Chinese 
herbal medicine (151) and B) cross section of fractured 3-D printed Carbon/PLA fiber composite (152).  
 
Moreover, the future research could be extended to controlling drug release via ME 
microspheres, which could exhibit, 1) lower initial burst release rate; it is important to treat 
A B 
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diseases requiring a continuous drug concentration over time. Thus, it would be interesting to 
prepare microspheres by adding two polymeric shells instead of single shell, as demonstrated 
by Kelmendi-Doko et al. (153). For example, they developed double-walled dexamethasone 
encapsulated microspheres with PLLA and PLGA to control the burst release.  2) Increased 
rate of drug release at specific time-points, e.g. when using antibiotics developing drug 
incorporated microsphere systems that can control ‘on/off’ drug release with an external 
stimulus could enable this. For example, to date, ferrogels used this on and off drug releasing 
technique (154). 
Specifically, for ME composite microspheres, it would be recommended to use 
polymers with higher piezoelectricity, as well as having good biocompatibility and 
biodegradability. Due to it toxicity, the use of CFO as magnetic component would also have to 
make way for other types of magnetic nanoparticles such as Fe3O4, which is currently widely 
used in biomedical applications. Having successfully demonstrated an ability to control the 
release of Dex, the future research could be extended to using different type of drugs. For 
example, Dex is a hydrophobic drug that does not readily dissolve in hydrophobic polymers 
such as PLA. Lastly, understanding how to achieve greater magnetically controlled drug 
release over longer time periods will be important. The CFO/PLA microspheres developed in 
in this study could also be tested in in-vitro and in-vivo cell studies in future.    
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